USD 2.25
↓ -0.505 (-18.33%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| PDSB | -18.3 | -32.0 | -31.4 | -25.5 | -36.4 | -63.9 | -79.4 | -7.4 | -99.0 | -99.0 |
| S&P 500 | -0.6 | -0.5 | 1.5 | 9.1 | 13.4 | 32.3 | 27.0 | 92.1 | 191.7 | 33587.3 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | PDSB |
| name | PDS Biotechnology Corporation |
| price | 2.25 |
| changes percentage | -18.3303 |
| change | -0.505 |
| day low | 1.53 |
| day high | 2.3395 |
| year high | 6.85 |
| year low | 1.53 |
| market cap | 82844550 |
| price avg 50 | 3.247 |
| price avg 200 | 3.68455 |
| exchange | NASDAQ |
| volume | 3350452 |
| avg volume | 320542 |
| open | 2.2 |
| previous close | 2.755 |
| eps | -1.23 |
| pe | -1.83 |
| earnings announcement | 2024-11-14T14:30:00.000+0000 |
| shares outstanding | 36819800 |
| timestamp | 2024-11-14 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001472091 | |||
| revenue | 0 | 0 | NaN |
| gross profit | -57326 | -49078 | -16.81 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 27762784 | 29431027 | -5.67 |
| operating expenses | 43045234 | 41672421 | 3.29 |
| interest income | 2902939 | 935180 | 210.42 |
| interest expense | 4205922 | 1316519 | 219.47 |
| ebitda | -40084969 | -41623343 | 3.70 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -43045234 | -41672421 | -3.29 |
| operating income ratio | 0 | 0 | NaN |
| net income | -42942198 | -40854855 | -5.11 |
| net income ratio | 0 | 0 | NaN |
| eps | -1.39 | -1.43 | 2.80 |
Gross Profit: Gross Profit decreased to 0 million in 2023 from 0 million in 2022 representing a change of -16.81%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 28 million in 2023 from 29 million in 2022 representing a change of -5.67%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 43 million in 2023 from 42 million in 2022 representing a change of 3.29%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -40 million in 2023 from -42 million in 2022 representing a change of 3.7%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income increased to -43 million in 2023 from -42 million in 2022 representing a change of -3.29%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -43 million in 2023 from -41 million in 2022 representing a change of -5.11%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -1.39 in 2023 from -1.39 in 2022 representing a change of 2.8%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001472091 | |||
| revenue | 0 | 0 | NaN |
| gross profit | -15128 | -14405 | -5.02 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 4527698 | 6704164 | -32.46 |
| operating expenses | 8684304 | 10083222 | -13.87 |
| interest income | 675209 | 668895 | 0.94 |
| interest expense | 1187971 | 1174745 | 1.13 |
| ebitda | -7993967 | -9414327 | 15.09 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -8684304 | -10097630 | 14.00 |
| operating income ratio | 0 | 0 | NaN |
| net income | -8327897 | -10603477 | 21.46 |
| net income ratio | 0 | 0 | NaN |
| eps | -0.23 | -0.3 | 23.33 |
Gross Profit: Gross Profit decreased to 0 million in 2024Q2 from 0 million in 2024Q1 representing a change of -5.02%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 5 million in 2024Q2 from 7 million in 2024Q1 representing a change of -32.46%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 9 million in 2024Q2 from 10 million in 2024Q1 representing a change of -13.87%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -8 million in 2024Q2 from -9 million in 2024Q1 representing a change of 15.09%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income increased to -9 million in 2024Q2 from -10 million in 2024Q1 representing a change of 14.0%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -8 million in 2024Q2 from -11 million in 2024Q1 representing a change of 21.46%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.23 in 2024Q2 from -0.23 in 2024Q1 representing a change of 23.33%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001472091 | |||
| total assets | 59390080 | 77007923 | -22.88 |
| total liabilities | 33259133 | 33005893 | 0.77 |
| total equity | 26130947 | 44002030 | -40.61 |
| cash and cash equivalents | 56560517 | 73820160 | -23.38 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 59055075 | 76480390 | -22.78 |
| total non current assets | 335005 | 527533 | -36.50 |
| total current liabilities | 13629977 | 9821036 | 38.78 |
| total non current liabilities | 19629156 | 23184857 | -15.34 |
| common stock | 10921 | 9956 | 9.69 |
| retained earnings | -144500615 | -101558417 | -42.28 |
| total debt | 23851617 | 23472898 | 1.61 |
Total Assets: Total Assets decreased to 59 million in 2023 from 77 million in 2022 representing a change of -22.88%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 33 million in 2023 from 33 million in 2022 representing a change of 0.77%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 26 million in 2023 from 44 million in 2022 representing a change of -40.61%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 57 million in 2023 from 74 million in 2022 representing a change of -23.38%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 59 million in 2023 from 76 million in 2022 representing a change of -22.78%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 14 million in 2023 from 10 million in 2022 representing a change of 38.78%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -145 million in 2023 from -102 million in 2022 representing a change of -42.28%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 24 million in 2023 from 23 million in 2022 representing a change of 1.61%. This indicates an increase in overall debt burden.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 9.69%. This indicates an increase in ownership interest.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001472091 | |||
| total assets | 60495947 | 69006366 | -12.33 |
| total liabilities | 29578077 | 31823321 | -7.06 |
| total equity | 30917870 | 37183045 | -16.85 |
| cash and cash equivalents | 57733724 | 66634417 | -13.36 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 60161476 | 68685765 | -12.41 |
| total non current assets | 334471 | 320600 | 4.33 |
| total current liabilities | 15674774 | 15063690 | 4.06 |
| total non current liabilities | 13903303 | 16759630 | -17.04 |
| common stock | 12137 | 12104 | 0.27 |
| retained earnings | -163431989 | -155104092 | -5.37 |
| total debt | 24378366 | 24108379 | 1.12 |
Total Assets: Total Assets decreased to 60 million in 2024Q2 from 69 million in 2024Q1 representing a change of -12.33%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 31 million in 2024Q2 from 37 million in 2024Q1 representing a change of -16.85%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 58 million in 2024Q2 from 67 million in 2024Q1 representing a change of -13.36%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 60 million in 2024Q2 from 69 million in 2024Q1 representing a change of -12.41%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 16 million in 2024Q2 from 15 million in 2024Q1 representing a change of 4.06%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -163 million in 2024Q2 from -155 million in 2024Q1 representing a change of -5.37%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 24 million in 2024Q2 from 24 million in 2024Q1 representing a change of 1.12%. This indicates an increase in overall debt burden.
Total Liabilities: Total Liabilities decreased to 30 million in 2024Q2 from 32 million in 2024Q1 representing a change of -7.06%. This indicates a decrease in overall liabilities.
Common Stock: Common Stock increased to 0 in 2024Q2 from 0 in 2024Q1 representing a change of 0.27%. This indicates an increase in ownership interest.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001472091 | |||
| net change in cash | -17259643.0 | 8577538 | -301.22 |
| operating cash flow | -33636136 | -25709706 | -30.83 |
| free cash flow | -33636140 | -25709706 | -30.83 |
| capital expenditure | -4 | 0 | NaN |
| depreciation and amortization | 17359 | 86 | 20084.88 |
| deferred income tax | -1965436 | 0 | NaN |
| stock based compensation | 7614321 | 5196156 | 46.54 |
| accounts payables | 5763537 | -90116 | 6495.69 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -4 | 0 | NaN |
| net cash used for investing activites | 0 | 0 | NaN |
| debt repayment | -59300 | 25000000 | -100.24 |
| common stock issued | 16126851 | 9856116 | 63.62 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 16376493 | 34287244 | -52.24 |
| cash at end of period | 56560517 | 73820160 | -23.38 |
| accounts receivables | 0 | 0 | NaN |
| cash at beginning of period | 73820160 | 65242622 | 13.15 |
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001472091 | |||
| operating cash flow | -8857908 | -9938189 | 10.87 |
| free cash flow | -8886907 | -9938189 | 10.58 |
| capital expenditure | -28999 | 0 | NaN |
| depreciation and amortization | 5459 | 14405 | -62.10 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 1795722 | 1630011 | 10.17 |
| accounts receivables | 0 | 0 | NaN |
| accounts payables | -2748341 | -981993 | -179.87 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -28999 | 0 | NaN |
| net cash used for investing activites | -28999 | 0 | NaN |
| debt repayment | -13786 | -13475.0 | -2.31 |
| common stock issued | 0 | 19494473 | -100.00 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -13786 | 20012089 | -100.07 |
| net change in cash | -8900693 | 10073900 | -188.35 |
| cash at end of period | 57733724 | 66634417 | -13.36 |
| cash at beginning of period | 66634417 | 56560517 | 17.81 |
Net Change in Cash: Net Change in Cash decreased to -9 million in 2024Q2 from 10 million in 2024Q1 representing a change of -188.35%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Stock-Based Compensation: Stock-Based Compensation increased to 2 million in 2024Q2 from 2 million in 2024Q1 representing a change of 10.17%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 3 million in 2024Q2 from 1 million in 2024Q1 representing a change of -179.87%. This indicates that the company has increased its outstanding obligations to its suppliers.
Operating Cash Flow: Operating Cash Flow increased to -9 million in 2024Q2 from -10 million in 2024Q1 representing a change of 10.87%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -9 million in 2024Q2 from -10 million in 2024Q1 representing a change of 10.58%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to 0 million in 2024Q2 from 0 million in 2024Q1 representing a change of nan%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -1.39 | -1.43 | 2.88 |
| operating cash flow per share | -1.09 | -0.9 | -20.89 |
| free cash flow per share | -1.09 | -0.9 | -20.89 |
| cash per share | 1.83 | 2.58 | -29.20 |
| book value per share | 0.84 | 1.54 | -45.13 |
| tangible book value per share | 0.84 | 1.54 | -45.13 |
| shareholders equity per share | 0.84 | 1.54 | -45.13 |
| interest debt per share | 0.9 | 0.85 | 5.84 |
| market cap | 153831440 | 377509717.2 | -59.25 |
| enterprise value | 121122540 | 327162455.2 | -62.98 |
| pe ratio | -3.58 | -9.24 | 61.23 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -4.57 | -14.68 | 68.85 |
| pfcf ratio | -4.57 | -14.68 | 68.85 |
| pb ratio | 5.89 | 8.58 | -31.38 |
| ptb ratio | 5.89 | 8.58 | -31.38 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -3.02 | -7.86 | 61.56 |
| ev to operating cash flow | -3.6 | -12.73 | 71.70 |
| ev to free cash flow | -3.6 | -12.73 | 71.70 |
| earnings yield | -0.28 | -0.11 | -157.94 |
| free cash flow yield | -0.22 | -0.07 | -221.06 |
| debt to equity | 0.91 | 0.52 | 73.16 |
| debt to assets | 0.4 | 0.3 | 33.34 |
| net debt to ebitda | 0.82 | 1.21 | -32.54 |
| current ratio | 4.33 | 7.79 | -44.36 |
| interest coverage | -10.23 | -31.65 | 67.67 |
| income quality | 0.78 | 0.63 | 24.47 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0.0 | 0 | NaN |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 5.13 | 7.03 | -27.00 |
| roic | -0.84 | -0.6 | -38.55 |
| return on tangible assets | -0.72 | -0.53 | -36.29 |
| graham net net | 0.75 | 1.43 | -47.25 |
| working capital | 45425098 | 66659354 | -31.85 |
| tangible asset value | 26130947 | 44002030 | -40.61 |
| net current asset value | 25795942 | 43474497 | -40.66 |
| invested capital | 45760103 | 67186887 | -31.89 |
| average receivables | 0 | 0 | NaN |
| average payables | 4101055.5 | 1264345 | 224.36 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 44460.29 | 9068.01 | 390.30 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0.01 | 0.04 | -79.60 |
| inventory turnover | 0 | 0 | NaN |
| roe | -1.64 | -0.93 | -76.99 |
| capex per share | 0.0 | 0 | NaN |
ROE: Return on Equity (ROE) decreased to -1.64 on 2023-12-31 from -0.93 on 2022-12-31, representing a change of -76.99%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 4.33 on 2023-12-31 from 7.79 on 2022-12-31, representing a change of -44.36%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -3.58 on 2023-12-31 from -9.24 on 2022-12-31, representing a change of 61.23%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.91 on 2023-12-31 from 0.52 on 2022-12-31, representing a change of 73.16%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-06-30 Q2 | 2024-03-31 Q1 | Q/Q change % | |
|---|---|---|---|
| PDSB | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -0.23 | -0.3 | 25.48 |
| operating cash flow per share | -0.24 | -0.29 | 15.43 |
| free cash flow per share | -0.24 | -0.29 | 15.15 |
| cash per share | 1.57 | 1.91 | -17.79 |
| book value per share | 0.84 | 1.07 | -21.10 |
| tangible book value per share | 0.84 | 1.07 | -21.10 |
| shareholders equity per share | 0.84 | 1.07 | -21.10 |
| interest debt per share | 0.69 | 0.72 | -4.00 |
| market cap | 111181489.83 | 139959797.4 | -20.56 |
| enterprise value | 77826131.83 | 97433759.4 | -20.12 |
| pe ratio | -3.34 | -3.3 | -1.14 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -12.55 | -14.08 | 10.87 |
| pfcf ratio | -12.51 | -14.08 | 11.16 |
| pb ratio | 3.6 | 3.76 | -4.46 |
| ptb ratio | 3.6 | 3.76 | -4.46 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -9.74 | -10.35 | 5.93 |
| ev to operating cash flow | -8.79 | -9.8 | 10.38 |
| ev to free cash flow | -8.76 | -9.8 | 10.68 |
| earnings yield | -0.07 | -0.08 | 1.13 |
| free cash flow yield | -0.08 | -0.07 | -12.57 |
| debt to equity | 0.78 | 0.64 | 21.69 |
| debt to assets | 0.4 | 0.35 | 15.42 |
| net debt to ebitda | 4.17 | 4.52 | -7.63 |
| current ratio | 3.84 | 4.56 | -15.83 |
| interest coverage | -7.31 | -8.6 | 14.95 |
| income quality | 1.06 | 0.94 | 13.48 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 5.31 | 0 | NaN |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 2.07 | 2.71 | -23.32 |
| roic | -0.14 | -0.17 | 13.68 |
| return on tangible assets | -0.14 | -0.15 | 10.41 |
| graham net net | 0.77 | 1.0 | -23.26 |
| working capital | 44486702 | 53622075 | -17.04 |
| tangible asset value | 30917870 | 37183045 | -16.85 |
| net current asset value | 30583399 | 36862444 | -17.03 |
| invested capital | 44821173 | 53942676 | -16.91 |
| average receivables | 0 | 0 | NaN |
| average payables | 4626660.5 | 6491827.5 | -28.73 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 19349.82 | 37492.18 | -48.39 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0.0 | 0.0 | 93.76 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.27 | -0.29 | 5.55 |
| capex per share | 0.0 | 0 | NaN |
ROE: Return on Equity (ROE) increased to -0.27 on 2024-06-30 Q2 from -0.29 on 2024-03-31 Q1, representing a change of 5.55%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -3.34 on 2024-06-30 Q2 from -3.30 on 2024-03-31 Q1, representing a change of -1.14%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 3.84 on 2024-06-30 Q2 from 4.56 on 2024-03-31 Q1, representing a change of -15.83%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.78 on 2024-06-30 Q2 from 0.64 on 2024-03-31 Q1, representing a change of 21.69%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is 1.06 which is lower than current price 2.25, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-14 11:18:51
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - Chief Executive Officer Lars Boesgaard - Chief Financial Officer Kirk Shepard - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Ali Rashidfarrokhi - B. Riley Robert LeBoyer - Noble Capital Markets Operator Good morning ladies and gentlemen and welcome to PDS Biotech's Third Quarter 2024 Results and Clinical Strategy Update Conference Call.
Sentiment: Positive
Publish Date: 2024-11-14 11:03:31
EMV Capital (AIM:EMVC) has noted the clinical progress update from portfolio company PDS Biotechnology alongside its third-quarter update. Frank Bedu-Addo, PDS chief executive, said: "Since our last update in August, we have been actively engaged with investors and clinicians to discuss our strategy and funding requirements for our VERSATILE-003 Phase 3 trial of Versamune® HPV + pembrolizumab compared to pembrolizumab as a potential treatment for first-line recurrent/metastatic HPV16-positive head and neck squamous cell cancer (HNSCC).
Sentiment: Neutral
Publish Date: 2024-11-06 08:00:00
PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will host a conference call to report financial results for the quarter ended September 30, 2024, and provide a clinical program update on Thursday, November 14, 2024, at 8:30 a.m. Eastern Time.
Sentiment: Positive
Publish Date: 2024-10-22 13:06:28
PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sentiment: Positive
Publish Date: 2024-10-15 11:00:24
ORLA, BABA and PDSB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 15, 2024.
Sentiment: Negative
Publish Date: 2024-10-02 08:00:00
100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune ® HPV combined with chemoradiation (N=8) 88% (15/17) of patients had a complete metabolic response IMMUNOCERV Phase 2 clinical trial results presented at ASTRO Annual Meeting 2024
Sentiment: Positive
Publish Date: 2024-09-23 10:39:38
PDS Biotechnology is focusing on an HPV-directed immunotherapy as its main near-term hope, with new data presented at the ESMO Congress. Strengths include promising clinical data and a focused pipeline, while risks involve typical biotech uncertainties and financial sustainability. The bottom-line summary suggests a cautious yet optimistic outlook, emphasizing the importance of upcoming clinical milestones and financial health.
Sentiment: Neutral
Publish Date: 2024-09-09 08:00:00
PRINCETON, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, will present updated data from the VERSATILE-002 trial evaluating first-line treatment with Versamune® HPV (formerly PDS0101) in combination with KEYTRUDA® (pembrolizumab) in patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) during a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2024 on September 14, 2024, in Barcelona, Spain.
Sentiment: Neutral
Publish Date: 2024-09-03 08:00:00
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
